This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
Ten Tweet round up of exciting CAR T trial in patients with SLE discussed last month - check it out while you can!
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) November 18, 2022
✳️ 10 tweets #NephJC catch-up ✳️
Here’s a recap of our 25th Oct #NephJC discussion on ‘Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus’ - better late than never!
Check out the paper at https://t.co/HxTcVC3PtH pic.twitter.com/y7o71HUPiZ
Is Anti-CD19 CAR T Cell therapy an efficacious and tolerable option for refractory SLE?
NSMC intern Susan Thanabalasingam explains it graphically
